Frankfurt
09.12.24
15:58 Uhr
1,312 Euro
+0,058
+4,63 %
+4,63 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | Orexo exits depression DTx alliance with GAIA | - | pharmaphorum | ||
| 02.12. | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 123 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| 25.10. | Orexo initiates new study of OX640 in participants with allergic rhinitis | 242 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10. | Orexo AB reports Q3 results | 1 | Seeking Alpha | ||
| 24.10. | Orexo Interim Report Q3 2024 | 298 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 04.10. | Orexo's Nomination Committee for the Annual General Meeting 2025 | 233 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
| 03.09. | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 263 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen | |
| 17.07. | Orexo AB GAAP EPS of -SEK1.04, revenue of SEK154M | 1 | Seeking Alpha | ||
| 17.07. | FDA issues CRL to Orexo's NDA for opioid overdose medication | 1 | Pharmaceutical Technology | ||
| 17.07. | Orexo Q2 2024 Interim Report | 335 | PR Newswire | UPPSALA, Sweden, July 17, 2024 /PRNewswire/ --
Making progress, while the OX124 review time extended
Q2 2024 highlights
Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK... ► Artikel lesen | |
| 16.07. | Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | 334 | PR Newswire | UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food... ► Artikel lesen | |
| 10.07. | Orexo AB's sustainability work ranked among top 5% by EcoVadis | 399 | PR Newswire | UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted... ► Artikel lesen | |
| 08.07. | Orexo: invitation to presentation of the Q2 2024 Interim Report | 362 | PR Newswire | UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm... ► Artikel lesen | |
| 10.05. | Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | 874 | PR Newswire | UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating... ► Artikel lesen | |
| 08.05. | Orexo Q1 2024 Interim Report | 390 | PR Newswire | UPPSALA, Sweden, May 8, 2024 /PRNewswire/ --
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net... ► Artikel lesen | |
| 26.04. | Report from Orexo AB's annual general meeting, 26 April 2024 | 292 | PR Newswire | UPPSALA, Sweden, April 26, 2024 /PRNewswire/ --
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance... ► Artikel lesen | |
| 17.04. | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | 299 | PR Newswire | UPPSALA, Sweden, April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another... ► Artikel lesen | |
| 02.04. | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | 377 | PR Newswire | UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the... ► Artikel lesen | |
| 28.03. | Orexo publishes the Annual and Sustainability Report for 2023 | 374 | PR Newswire | UPPSALA, Sweden, March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report... ► Artikel lesen | |
| 22.03. | Orexo AB: Notice of Annual General Meeting of Orexo | 364 | PR Newswire | UPPSALA, Sweden, March 22, 2024 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,234 | -0,09 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Fiscal 2025 Second Quarter Results | NASDAQ | TSX: ACB
Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%
Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global... ► Artikel lesen | |
| ABBVIE | 167,34 | +1,20 % | AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal.In the study, patients treated with tavapadon... ► Artikel lesen | |
| TILRAY BRANDS | 1,241 | +2,77 % | Die Hoffnung schwindet: Tilray, Canopy & Co. brechen mit DEA-Anhörung ein. Nun wird's brenzlig! | © Foto: Piyapong Thongdumhyu - 123rf StockfotoHoffnungsvoll sieht anders aus. Am Montag (02. Dezember) fand die DEA-Anhörung zur vorgeschlagenen Neuklassifizierung von Cannabis statt. Die Aktienkurse... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 55,69 | -0,93 % | Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead | ||
| TEVA | 16,850 | +2,43 % | Teva Pharmaceutical Industries Ltd: Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE | AJOVY®
(Fremanezumab) reduzierte die monatlichen Migränetage (MMD) und monatlichen Kopfschmerztage (MHD) im Vergleich zu Placebo über einen Zeitraum von 12 Wochen bei pädiatrischen Patienten im... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 449,05 | +2,70 % | Vertex Pharmaceuticals: "Eine der hochwertigsten Qualitätsaktien" | Die amerikanische Investmentbank JPMorgan hat sich über die Aussichten der Pharmabranche im Jahr 2025 geäußert und ist insbesondere für Vertex Pharmaceuticals optimistisch gestimmt, das sind die Gründe.... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,200 | +6,30 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration | - Topline data for Phase 3 pivotal program anticipated in 2026 - WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 67,07 | -0,95 % | Edwards Lifesciences Projects 2025 Constant Currency Sales Growth Of 8% - 10% | WASHINGTON (dpa-AFX) - Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is projecting 2025 constant currency... ► Artikel lesen | |
| BAUSCH HEALTH | 7,968 | +3,08 % | Bausch Health Companies Inc.: Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day | LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation... ► Artikel lesen | |
| BIONANO GENOMICS | 0,258 | +10,66 % | Bionano Genomics, Inc. - 8-K, Current Report | ||
| ASTRIA THERAPEUTICS | 9,350 | -4,59 % | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| AMARIN | 0,462 | +1,32 % | Amarin Corporation plc: Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update | -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation --- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA... ► Artikel lesen | |
| OPKO HEALTH | 1,560 | +3,93 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| JAGUAR HEALTH | 1,000 | +2,85 % | Jaguar Health, Inc.: Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium | Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of CTD SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2024... ► Artikel lesen | |
| ENDO | - | - | Endo, Inc.: Endo Receives U.S. FDA Approval of Manufacturing Facility in Indore, India | 20,000-square-foot site increases Endo's sterile injectable production capacityThis marks the site's first U.S. FDA approval Endo is investing and innovating in its Injectable Solutions businessMALVERN... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.
